Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

<< Previous

Bullboard Posts

Next >>

Post by B52paulon Feb 19, 2021 8:13pm

514 Views

Post# 32616845

SEDI Insider Filings 2021-02-19

Recent filings
Filed 2021-02-19 14:23 Tx date 2018-10-17	$AGN Algernon Pharmaceuticals Inc.	Attariwala, Rajpaul 4 - Director of Issuer Direct Ownership	Common Shares 37 - Stock split or consolidation	-1,000,000 vol	1,000,000
Filed 2021-02-19 14:22 Tx date 2021-01-21	$AGN Algernon Pharmaceuticals Inc.	Attariwala, Rajpaul 4 - Director of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	+73,118 vol	1,143,722
Filed 2021-02-19 14:22 Tx date 2020-09-29	$AGN Algernon Pharmaceuticals Inc.	Attariwala, Rajpaul 4 - Director of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	+70,604 vol	1,070,604
Filed 2021-02-19 14:21 Tx date 2021-01-21	$AGN Algernon Pharmaceuticals Inc.	Attariwala, Rajpaul 4 - Director of Issuer Direct Ownership	Rights RSUs 57 - Exercise of rights	-82,500 vol	85,000
Filed 2021-02-19 14:20 Tx date 2020-09-29	$AGN Algernon Pharmaceuticals Inc.	Attariwala, Rajpaul 4 - Director of Issuer Direct Ownership	Rights RSUs 57 - Exercise of rights	-82,500 vol	167,500
Filed 2021-02-19 14:17 Tx date 2020-07-23	$AGN Algernon Pharmaceuticals Inc.	Attariwala, Rajpaul 4 - Director of Issuer Direct Ownership	Rights RSUs 56 - Grant of rights	+250,000 vol	250,000
Filed 2021-02-19 14:17 Tx date 2015-10-26	$AGN Algernon Pharmaceuticals Inc.	Attariwala, Rajpaul 4 - Director of Issuer Direct Ownership	Rights RSUs 00 - Opening Balance-Initial SEDI Report
Filed 2021-02-19 14:15 Tx date 2020-10-26	$AGN Algernon Pharmaceuticals Inc.	Attariwala, Rajpaul 4 - Director of Issuer Direct Ownership	Warrants 55 - Expiration of warrants	-1,000,000 vol	0
Filed 2021-02-19 14:13 Tx date 2020-04-13	$AGN Algernon Pharmaceuticals Inc.	Attariwala, Rajpaul 4 - Director of Issuer Direct Ownership	Options 50 - Grant of options	+200,000 vol	750,000
Filed 2021-02-19 14:11 Tx date 2018-10-17	$AGN Algernon Pharmaceuticals Inc.	Attariwala, Rajpaul 4 - Director of Issuer Direct Ownership	Options 37 - Stock split or consolidation	-50,000 vol	350,000
Filed 2021-02-19 14:10 Tx date 2018-10-17	$AGN Algernon Pharmaceuticals Inc.	Attariwala, Rajpaul 4 - Director of Issuer Direct Ownership	Options 37 - Stock split or consolidation	-50,000 vol	400,000
Filed 2021-02-19 14:08 Tx date 2021-02-01	$AGN Algernon Pharmaceuticals Inc.	Attariwala, Rajpaul 4 - Director of Issuer Direct Ownership	Options 52 - Expiration of options	-250,000 vol	500,000